Rolapitant Improves QoL in Patients Receiving HEC or MEC

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life compared with a 5-HT3 receptor antagonist, dexamethasone, and placebo in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), a study published in the journal Supportive Care in Cancer has shown.1

Previous reports of phase 3 trials demonstrated that the addition of the substance P/neurokinin 1 receptor antagonist, rolapitant, to standard therapy improves protection against chemotherapy-induced nausea and vomiting (CINV) in patients receiving HEC or MEC.

Continue Reading Below

In those studies, investigators also assessed the impact of rolapitant on quality of life. Patients completed the Functional Living Index-Emesis (FLIE) questionnaire on day 6 of cycle 1; FLIE total score, as well as nausea and vomiting domain scores and the proportion of patients with no impact on daily life, were used as end points.

Results showed that in patients receiving HEC, rolapitant significantly improved the FLIE total score (P <.001), nausea score (P <.05), and vomiting score (P <.001) compared with the control regimen.

Similar results were observed in patients receiving MEC or an anthracycline plus cyclophosphamide.

The researchers found that 73.2% of patients receiving MEC or an anthracycline plus cyclophosphamide reported no impact on daily life with rolapitant vs 67.4% of those who received placebo (P =.027).

Reference

1. Chasen M, Urban L, Schnadig I, et al. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Supp Care Cancer. 2016 Aug 24. doi: 10.1007/s00520-016-3388-7. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs